Insights on the Biologics Global Market to 2027 - by Source, Product, Disease, Manufacturing and Region

DUBLIN, July 19, 2022 /PRNewswire/ -- The "Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global biologics market reached a value of US$ 294 billion in 2021. Looking forward, the market is projected to reach US$ 501.9 billion by 2027, exhibiting a CAGR of 9.25% during 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms.

These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases.

The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19).

Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn's diseases.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi.

Key Questions Answered in This Report

• How has the global biologics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global biologics market?
• What are the key regional markets?
• What is the breakup of the market based on the source?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the disease?
• What is the breakup of the market based on the manufacturing?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global biologics market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Biologics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Source
6.1 Microbial
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Mammalian
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Product
7.1 Monoclonal Antibodies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Vaccines
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Recombinant Proteins
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Antisense, RNAi and Molecular Therapy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast

8 Market Breakup by Disease
8.1 Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Immunological Disorders
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cardiovascular Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Hematological Disorders
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by Manufacturing
9.1 Outsourced
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 In-House
9.2.1 Market Trends
9.2.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 AbbVie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Amgen Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 AstraZeneca plc
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche Ltd
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 GlaxoSmithKline plc
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanofi
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/b0dbyx

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets